# Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.

> **NCT03552276** · PHASE2,PHASE3 · COMPLETED · sponsor: **Sun Pharmaceutical Industries Limited** · enrollment: 281 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** SUNPG18_07 I (Tildrakizumab 200 mg)
- **DRUG:** SUNPG18_07 II (Tildrakizumab 100 mg)

## Key facts

- **NCT ID:** NCT03552276
- **Lead sponsor:** Sun Pharmaceutical Industries Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-11
- **Primary completion:** 2023-09-18
- **Final completion:** 2023-09-18
- **Target enrollment:** 281 (ACTUAL)
- **Last updated:** 2024-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03552276

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03552276, "Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03552276. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*